Gastroenterology Unit, Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi 1, 67100, L'Aquila, Italy.
Andrology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
BMC Gastroenterol. 2022 Mar 3;22(1):92. doi: 10.1186/s12876-022-02157-5.
Mucosal healing (MH) evaluated by endoscopy is a novel target of therapy in UC as it is associated with improved long-term outcomes. It is defined based on the Mayo endoscopic score (MES), but it is still to define whether a value of MES 0 or 1 should be the target. The purpose of this paper is to present the results of a systematic review with meta-analysis which compares long-term outcomes of patients in steroid-free clinical remission with MES 0 with those with MES 1.
A systematic electronic search of the literature was performed using Medline, Scopus, and CENTRAL through December 2020 (PROSPERO n:CRD42020179333). The studies concerned UC patients, in steroid-free clinical remission, with MES of 0 or 1, and with at least 12-months of follow-up.
Out of 4611 citations, 15 eligible studies were identified. Increases in clinical relapse among patients with MES 1 were observed in all the studies included in this review, suggesting that MES of 1 have a higher risk of relapse than a score of 0. MES 0 patients displayed a lower risk of clinical relapse (OR 0.33; 95% CI 0.26-0.43; I 13%) irrespective of the follow-up time (12-months or longer). On the other hand, no differences were found comparing MES 0 versus MES 1 about the risk of hospitalization or colectomy.
MES 0 is associated with a lower rate of clinical relapse than is MES 1. For this reason, MES 0, rather than MES 0-1, should be considered the therapeutic target for patients with UC.
内镜评估的黏膜愈合(MH)是 UC 治疗的新靶点,因为它与改善长期预后相关。它基于 Mayo 内镜评分(MES)定义,但仍需要确定 MES 0 或 1 是否应作为目标。本文旨在介绍一项系统评价和荟萃分析的结果,该分析比较了无类固醇临床缓解且 MES 0 与 MES 1 的 UC 患者的长期结局。
通过 Medline、Scopus 和 CENTRAL 进行系统电子文献检索,检索时间截至 2020 年 12 月(PROSPERO 编号:CRD42020179333)。研究涉及无类固醇临床缓解、MES 0 或 1 的 UC 患者,且随访时间至少 12 个月。
在 4611 条引文中有 15 项符合条件的研究。本综述纳入的所有研究均观察到 MES 1 患者的临床复发率增加,这表明 MES 1 比 MES 0 有更高的复发风险。MES 0 患者的临床复发风险较低(OR 0.33;95%CI 0.26-0.43;I 13%),无论随访时间(12 个月或更长)如何。另一方面,在比较 MES 0 与 MES 1 患者的住院或结肠切除风险时,未发现差异。
MES 0 与 MES 1 相比,临床复发率较低。因此,MES 0 而不是 MES 0-1 应被视为 UC 患者的治疗目标。